NCT07193966View on ClinicalTrials.gov

NG2 and DLL3 CAR-T Cells Targeting Melanoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Melanoma
Interventions
BIOLOGICAL

NG2 and DLL3 CAR-T cells

Infusion of NG2 and DLL3-specific CAR-T via intravenous route

Trial Locations (1)

518000

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER

NCT07193966 - NG2 and DLL3 CAR-T Cells Targeting Melanoma | Biotech Hunter | Biotech Hunter